Abstract

Uterine leiomyomas (ULs) constitute a considerable health burden in the general female population. The fumarate hydratase (FH) deficient subtype is found in up to 1.6% and can occur in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. We sequenced 13 FH deficient ULs from a previous immunohistochemical screen using a targeted panel and identified biallelic FH variants in all. In eight, we found an FH point mutation (two truncating, six missense) with evidence for loss of the second allele. Variant allele-frequencies in all cases with a point mutation pointed to somatic variants. Spatial clustering of the identified missense variants in the lyase domain indicated altered fumarase oligomerization with subsequent degradation as explanation for the observed FH deficiency. Biallelic FH deletions in five tumors confirm the importance of copy number loss as mutational mechanism. By curating all pathogenic FH variants and calculating their population frequency, we estimate a carrier frequency of up to 1/2,563. Comparing with the prevalence of FH deficient ULs, we conclude that most are sporadic and estimate 2.7–13.9% of females with an FH deficient UL to carry a germline FH variant. Further prospective tumor/normal sequencing studies are needed to develop a reliable screening strategy for HLRCC in women with ULs.

Highlights

  • Uterine leiomyomas (ULs; fibroids) are benign smooth muscle tumors of the myometrium with an estimated lifetime risk of 70% [1]

  • None of the 13 individuals presented with other typical features of hereditary leiomyomatosis and renal cell carcinoma (HLRCC) besides their fumarate hydratase (FH) deficient ULs, indicating sporadic events

  • Identifying individuals who carry a pathogenic variant in the FH gene is considered important as they have an increased lifetime risk of about 15% [55] for the aggressive renal cell carcinomas (RCC) type associated with HLRCC

Read more

Summary

Introduction

Uterine leiomyomas (ULs; fibroids) are benign smooth muscle tumors of the myometrium with an estimated lifetime risk of 70% [1]. As about 30% of women are symptomatic and present with abdominal pain, vaginal bleeding, or anemia [2, 3], ULs represent a considerable health burden [4]. These hormone dependent tumors usually do not occur before adolescence, but increase in size in the reproductive period and frequently decrease in size after menopause [2]. The authors could associate the combined polygenic risk with the most common UL subtype, positive for somatic MED12 mutations [10]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call